3:35 PM
 | 
Jul 03, 2014
 |  BC Extra  |  Company News

FDA accepts NDA for InterMune's pirfenidone

FDA accepted for review a resubmitted NDA from InterMune Inc. (NASDAQ:ITMN) for pirfenidone to treat idiopathic pulmonary fibrosis (IPF). The agency designated the NDA a Class 2 resubmission, with a Nov. 23 PDUFA date, InterMune said. In 2010, FDA issued a complete response letter...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >